Form 4: Black Diamond Therapeutics Director Ali Behbahani Acquires Stock Options

Director Ali Behbahani acquired 30,550 stock options in Black Diamond Therapeutics, Inc. on June 6, 2024.

Summary

• Ali Behbahani, a director of Black Diamond Therapeutics, Inc., acquired 30,550 stock options on June 6, 2024.
• The options have an exercise price of $4.65.
• The options vest fully on the earlier of June 6, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued service.
• The expiration date for the options is June 5, 2034.
• A power of attorney is in place, authorizing Zachary Bambach, Nicole Hatcher, and Stephanie Brecher to act on Behbahani's behalf for SEC filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of stock options by a director is generally a good sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, suggesting an expectation of ongoing involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and commitment.

Key Dates